sutimlimab
Selected indexed studies
- Sutimlimab: First Approval. (Drugs, 2022) [PMID:35412113]
- Sutimlimab in Cold Agglutinin Disease. (N Engl J Med, 2021) [PMID:33826820]
- Sutimlimab. (, 2006) [PMID:36780408]
_Worker-drafted node — pending editorial review._
Connections
sutimlimab is a side effect of
Sources
- Sutimlimab: First Approval. (2022) pubmed
- Sutimlimab in Cold Agglutinin Disease. (2021) pubmed
- Sutimlimab. (2006) pubmed
- Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. (2022) pubmed
- Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis. (2023) pubmed
- Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? (2022) pubmed
- Sutimlimab for the Treatment of Cold Agglutinin Disease. (2023) pubmed
- Complement-directed therapy for cold agglutinin disease: sutimlimab. (2023) pubmed
- A virtuosic CADENZA played by sutimlimab. (2022) pubmed
- Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study. (2023) pubmed